Invivyd, Inc. (IVVD): R&D Expense
$38.31M
Year ended 2025-12-31
$78.19M
Trailing 12 months to 2026-06-30
-40.2%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $38.31M | -72.1% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $137.25M | -13.5% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $158.66M | -11.5% | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $179.21M | -2.0% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $182.89M | n/a | 2023-03-23, From 2021-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | 2025-12-31 | $38.31M | -72.1% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $19.57M | +50.9% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $9.08M | +33.1% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $250.0K | -18.6% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $455.97M | -10.0% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $33.56M | -34.6% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $89.95M | -54.9% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $134.67M | +5.7% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $112.67M | +1.0% |
Compare IVVD, PLX, CSBR, FENC side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗